{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:32:48Z","timestamp":1793377968332,"version":"4.5.0"},"reference-count":0,"publisher":"Saudi Heart Association","issue":"3","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Saudi Heart Association"],"abstract":"<jats:p>Objectives: Aortic stenosis is the most common valvular heart disease globally; while transcatheter aortic valve replacement (TAVR) has proven to be a competitive alternative to surgical aortic valve replacement (SAVR) and revolutionized treatment, its safety and efficacy has yet to be comprehensively assessed against SAVR for certain subsets of aortic stenosis patients; therefore, this study aims to systematically analyze all the available clinical evidence from randomized clinical trials on TAVR versus SAVR among intermediate and low-risk patients with severe symptomatic aortic stenosis.\nMethodology: We performed a systematic review of the randomized controlled trials (RCT), studies comparing TAVR and SAVR in low- and intermediate-risk patients were identified by a comprehensive search of the major databases. Mortality, stroke, length of stay, and other perioperative outcomes were assessed. Results: A comprehensive screening of 14,384 records identified 9 studies, encompassing 8,884 patients with a mean age of 77.76 years and 49.47% male. TAVR demonstrated a significantly lower all-cause mortality at both 30 days and 1 year compared to SAVR, with comparable outcomes at 2 years, underscoring its potential for enhanced survival. Stroke incidence was markedly lower with TAVR at both 30 days and 1 year, highlighting its favorable neurological safety profile. Additionally, TAVR showed a reduced rate of myocardial infarction within the initial 30 days post-procedure. Prosthetic valve endocarditis rates remained low and comparable between the two approaches at both 30 days and 1 year. Notably, TAVR was associated with a significantly shorter hospital stay, suggesting a faster recovery trajectory and improved patient throughput. These findings collectively emphasize the superior efficacy and safety profile of TAVR over SAVR.\nConclusion: TAVR may serve as a viable therapeutic option for intermediate and low-risk patients with severe symptomatic aortic stenosis. Future research should focus on long-term outcomes and TAVR device durability, especially in younger, lower-risk populations.<\/jats:p>","DOI":"10.37616\/2212-5043.1393","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T13:59:41Z","timestamp":1728741581000},"page":"242-251","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Elderly Patients with Severe Symptomatic Aortic Stenosis: A Systematic Review"],"prefix":"10.37616","volume":"36","author":[{"given":"Omar","family":"Hamodat","sequence":"first","affiliation":[{"name":"University of Sharjah, College of medicine, Sharjah, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Almuzainy","sequence":"additional","affiliation":[{"name":"University of Sharjah, College of medicine, Sharjah, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Nizar","sequence":"additional","affiliation":[{"name":"University of Sharjah, College of medicine, Sharjah, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"24531","published-online":{"date-parts":[[2024,10,11]]},"container-title":["Journal of the Saudi Heart Association"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:37:48Z","timestamp":1793374668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.j-saudi-heart.com\/jsha\/vol36\/iss3\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,11]]}},"URL":"https:\/\/doi.org\/10.37616\/2212-5043.1393","relation":{},"ISSN":["2212-5043"],"issn-type":[{"value":"2212-5043","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}